2024
Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020
Ajjawi I, Loeb S, Cooperberg M, Catalona W, Gross C, Ma X, Leapman M. Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020. JAMA 2024, 332 PMID: 39565605, PMCID: PMC11579888, DOI: 10.1001/jama.2024.20580.Peer-Reviewed Original Research
2023
Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study
Marks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar M, Pantel H, Berger E, Boffa D, Cavallo J, Leapman M. Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study. JMIR Cancer 2023, 9: e45518. PMID: 37917149, PMCID: PMC10654905, DOI: 10.2196/45518.Peer-Reviewed Original ResearchCancer HospitalCancer careTelehealth availabilityTotal admissionsTelehealth servicesCancer typesBreast cancer careComprehensive cancer programsCross-sectional studySkin cancer careFacility-level factorsNational Cancer InstituteCOVID-19 pandemicTelehealth visitsAccountable care organizationsCommon cancerCancer programsOutpatient careCancer sitesNew patientsCancer InstitutePatientsSkin cancerHospitalMost hospitals
2021
Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States
Holler J, Hakam N, Nabavizadeh B, Sadighian M, Shibley W, Li K, Weiser L, Rios N, Enriquez A, Leapman M, Amend G, Breyer B. Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States. Urology Practice 2021, 9: 56-63. PMID: 37145560, DOI: 10.1097/upj.0000000000000275.Peer-Reviewed Original ResearchUrological cancersActive treatmentCancer campaignsMajor urological cancersPrimary cancer typeCross-sectional studyWilcoxon rank sum testRank sum testRecipient ageMultivariable analysisPatient populationTesticular malignancyMalignancy typeTesticular cancerKidney cancerMedical careCancerCancer typesMedical expensesFinancial burdenOutcomesBladderKruskal-WallisProstateAge